- Home
- CTNM vs NATH Comparison
CTNM vs NATH Comparison
Compare CTNM & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNM | NATH |
|---|---|---|
| Founded | 2009 | 1916 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Restaurants |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.0M | 411.7M |
| IPO Year | 2024 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CTNM | NATH |
|---|---|---|
| Price | $13.06 | $100.73 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 331.7K | 20.4K |
| Earning Date | 03-05-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 1.98% |
| EPS Growth | 0.46 | ★ 22.29 |
| EPS | N/A | ★ 4.17 |
| Revenue | N/A | ★ $104,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $24.18 |
| Revenue Growth | N/A | ★ 7.81 |
| 52 Week Low | $3.35 | $88.00 |
| 52 Week High | $16.33 | $118.32 |
Technical Indicators
Market Signals| Indicator | CTNM | NATH |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 54.64 |
| Support Level | $10.17 | $100.25 |
| Resistance Level | $13.18 | $102.05 |
| Average True Range (ATR) | 1.07 | 0.36 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 42.15 | 62.67 |
Price Performance
Historical ComparisonAbout CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.